Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000159

Drug Information
NameGatifloxacin
SynonymsCHEBI:5280; Kinome_3137; MLS000040259; BRD-A74980173-001-02-8; (+-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; Gatifloxacin; SAM002589955; PD-135432; Zymaxid; KBio2_007578; 180200-66-2; 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; MLS000759493; Tequin; SMR000043336; Spectrum3_000999; 112811-59-3; BMS-206584; AM 1155; 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-; Gatiflo; 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; AM-1155 (*Sesquihydrate*); Zymer; CG-5501; Gatifloxacin & Gamma Interferon; Gatifloxacin (TN); 160738-57-8; I06-2286; AM-1155; S1340_Sellekc; KBio3_001917; D08011; Spectrum2_000487; KBioGR_001613; NCGC00095126-02; 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid; S1340_Selleck; Gatifloxacin [USAN:INN]; 1-Cyclopropyl-1,4-dihydro-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; MolPort-001-738-626; Spectrum_001909; NCGC00178525-01; Zymer (TN); TL8001438; HMS2090K10; BMS-206584-01; I06-2287; PD135432; CPD000043336; C07661; KBio2_002442; KBio2_005010; BSPBio_002697; AC1L1K82; Tequin in dextrose 5% in plastic container; FT-0082686; Zymar; Spectrum4_001127; KBioSS_002448; GTFX; Spectrum5_001468; HMS2093G06; HMS1922J15; NCGC00095126-01; Gatispan; CHEMBL31; CG 5501; PD 135432; Gatilox; STK801620; SAM001246715; AC-1944; Gatiflo,Tequin and Zymar, Gatifloxacin; BMS 206584-01; AKOS004119932; BB_SC-1123; DB01044; SPBio_000353; SPECTRUM1504272; Gaity; Gatifloxacin (INN); Bonoq; CID5379; LS-184402; Gatiquin
Trade NameGatiflo; Tequin; Zymar
CompanyBristol-Myers Squibb
IndicationRespiratory tract infections
[ICD9: 460-519   ICD10: J00-J99]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C19H22FN3O4/c1-10-8-22(6-5-21-10)16-14(20)7-12-15(18(16)27-2)2
3(11-3-4-11)9-13(17(12)24)19(25)26/h7,9-11,21H,3-6,8H2,1-2H3,(H,2
5,26)
InChIKeyXUBOMFCQGDBHNK-UHFFFAOYSA-N
Canonical SMILESCC1CN(CCN1)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F    
Therapeutic ClassAnti-Infective Agents
CAS NumberCAS 112811-59-3
FormulaC19H22FN3O4
PubChem Compound IDCID 5379.
PubChem Substance IDSID 9863.
SuperDrug ATC IDJ01MA16; S01AE06
SuperDrug CAS ID112811593;
TargetDNA topoisomerase IIInhibitor[2]
DNA topoisomerase IIMultitarget[2]
Topoisomerase IVInhibitor[2]
Topoisomerase IVMultitarget[2]
Ref 1Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8. To Reference
Ref 2Antimicrob Agents Chemother. 1998 Oct;42(10):2678-81.Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543